Open Text Corporation (OTEX) Stock Price Today
Aura AI Summary
Key Stats
- $5.92BMarket Cap
- -Volume
- TechnologySector
- $39.6952W High
- $20.0152W Low
- -Typical Hold Time
- $10.94BEnterprise Value
- 4.56%Div Yield
- -Trading Activity
Track Open Text Corporation (OTEX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Open Text Corporation has traded between a low of $20.01 and a high of $39.69, highlighting its annual price range. Buy and sell Open Text Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Most Recent News
Consortium including Jeff Bezos buys minority stake in Liverpool FC for $7B amid Premier League losses.
A consortium led by Jeff Bezos has acquired a minority stake in Liverpool Football Club in a deal valued at over $7 billion. This comes nearly 16 years after Fenway Sports Group rescued the club, now cashing out with significant returns following Liv...

Cambium Networks' new ePMP 5.12 software boosts performance and cuts costs by turning subscriber modules into access points.
Cambium Networks announced that its ePMP 4000 Series has shipped over 220,000 radios globally, including 50,000 6 GHz radios in North America. The new ePMP Software Release 5.12, available as a free upgrade, improves performance and offers a cost-eff...

Rhythm Pharmaceuticals expands rare disease drug into broad MC4R franchise with strong demand and growth potential
Rhythm Pharmaceuticals is evolving from a single rare disease drug company to a broader therapeutic franchise focused on MC4R treatments. Their drug IMCIVREE has gained approval for AHO and shows strong demand with over 400 patient starts, supported ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.